Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Seiichi Villalona, Xin Wang, Peter Gabriel, Abigail Doucette, Shannon R McCurdy, Alexander Perl, Selina M Luger, Noelle V. Frey, Ximena Jordan Bruno, Elizabeth O Hexner, Daria V Babushok, David L. Porter, Alison W Loren, Keith W Pratz, Catherine Lai

Blood (2023) 142 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2023-178247

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cristian C. Taborda, Shannon H Gier, Avery W Stivale, Alexander E. Perl, Saar Gill, Daria V. Babushok, Elizabeth O. Hexner, Noelle V. Frey, Catherine Lai, Ximena Jordan Bruno, Mary Ellen Martin, Ivan Maillard, David L. Porter, Alison W. Loren, Keith W. Pratz, Selina M. Luger, Phyllis A. Gimotty, Shannon R. McCurdy

Blood (2022) 140 (Supplement 1): 10825–10827.

https://doi.org/10.1182/blood-2022-169924

Published: 2022

Journal Articles

Patient-Reported Outcome Measures in Newly Diagnosed Acute Myeloid Leukemia: An Exploratory Analysis of Real-World Data

Xin Wang, Peter Gabriel, Abigail Doucette, Phyllis A. Gimotty, Kelly D. Getz, Samuel Takvorian, Alexander E. Perl, Shannon R. McCurdy, Selina M. Luger, Noelle V. Frey, Alison W. Loren, Elizabeth O. Hexner, Daria V. Babushok, David L. Porter, Keith W. Pratz, Catherine Lai

Blood (2022) 140 (Supplement 1): 13287–13288.

https://doi.org/10.1182/blood-2022-170733

Published: 2022

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Blood (2022) 140 (Supplement 1): 8019–8021.

https://doi.org/10.1182/blood-2022-167411

Published: 2022

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

Journal Articles

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

Nosha Farhadfar, Michael Weaver, Zeina Al-Mansour, Jean C. Yi, Heather S. L. Jim, Alison W. Loren, Navneet S. Majhail, Victoria Whalen, John R. Wingard, Debra Lynch Kelly, Karen Syrjala

Blood (2021) 138 (Supplement 1): 3932.

https://doi.org/10.1182/blood-2021-147968

Published: 2021

Journal Articles

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Blood (2021) 138 (Supplement 1): 469.

https://doi.org/10.1182/blood-2021-153955

Published: 2021

Journal Articles

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, Noelle V Frey

Blood (2021) 138 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2021-153920

Published: 2021

Journal Articles

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, Keith W. Pratz

Blood (2021) 138 (Supplement 1): 795.

https://doi.org/10.1182/blood-2021-149158

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138542

Published: 2020

NARROW

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Patient-Reported Outcome Measures in Newly Diagnosed Acute Myeloid Leukemia: An Exploratory Analysis of Real-World Data

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only